

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MÜLLER et al.

Serial No. 09/912,414

Filed: July 26, 2001

For: **TRANSCRIPTION FACTOR E2F DNA-BINDING DOMAIN  
INHIBITOR PEPTIDES AND THEIR USE**

\* \* \* \* \*



Atty. Ref.: 620-151

Group:

Examiner:

November 19, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**AMENDMENT**

Responsive to the Notice to File Missing Parts dated September 17, 2001 (copy attached), entry and consideration of the following amendments and remarks are requested.

**IN THE SPECIFICATION**

Insert the attached copy of the specification for that which was originally filed.

Insert the attached Sequence Listing after the claims pages.

**IN THE ABSTRACT**

Insert the attached Abstract for a copy of the same which was originally filed.

**REMARKS**

Reconsideration is requested.

RECEIVED

**MÜLLER et al.**  
**Serial No. 09/912,414**

A new specification has been submitted which complies with Rule 52 with regard to the margin. In all other respects, the attached copy of the specification is the same as the originally filed specification. No new matter has been added.

The attached paper and computer-readable copies of the Sequence Listing are the same. No new matter has been added. A separate Statement to this effect is attached.

The attached Abstract has been submitted in place of that which was originally filed. No new matter has been added.

Attached is a certified copy of the priority document, GB 9901710.5. Acknowledgement of receipt of the same in the Examiner's next correspondence is requested.

Nothing further is believed to be required in response to the attached Notice to File Missing Parts dated September 17, 2001, however the Office is requested to contact the undersigned if otherwise.

An early and favorable Action on the merits of the claimed invention is requested.

**MÜLLER et al.**  
**Serial No. 09/912,414**

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



**B. J. Sadoff**  
Reg. No. 36,663

**BJS:eaw**

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

FILED IN 15-11-2014

**ABSTRACT OF THE DISCLOSURE**

The present invention provides peptides which bind to the DNA binding domain of transcription factor E2F, and inhibit cell cycle progression. Peptides include FWLRFT (SEQ ID NO:1); WVRWHF (SEQ ID NO:2); WHFIFW (SEQ ID NO:3); IWLSGLSRGVVVSFP (SEQ ID NO:4); and GSRILTFRSGSWYAS (SEQ ID NO:5) and derivatives based upon these sequences. Compositions and the use of the peptides in inhibiting cell cycle progression, such as in uncontrolled cell proliferation, are also provided.